4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. is a late-stage biotechnology company focused on developing adeno-associated virus (AAV) vectors using its proprietary Therapeutic Vector Evolution platform. The company designs targeted vectors for gene therapy applications. Its lead product candidate is 4D-150, designed for retinal vascular diseases such as wet age-related macular degeneration and diabetic macular edema, aiming to provide multi-year sustained anti-VEGF production via intravitreal injection. Another candidate, 4D-710, is in early-stage study for cystic fibrosis. Preclinical programs include 4D-175 for geographic atrophy and 4D-725 for alpha-1 antitrypsin deficiency lung disease. The company operates in the Netherlands and the United States.

4D Molecular Therapeutics is publicly traded on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol FDMT. Its shares are denominated in US dollars (USD), reflecting its primary listing in the United States. The company's headquarters are located in Emeryville, California, and it also has operations in the Netherlands.

4D Molecular Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing gene therapies using proprietary AAV vector technology. Its work involves late-stage clinical development for retinal diseases and early-stage studies for other conditions like cystic fibrosis and lung disease, positioning it within the broader biotech landscape.

4D Molecular Therapeutics is headquartered in Emeryville, California, United States. The company also has operations in the Netherlands, indicating a presence in both North America and Europe. Its research and development activities target global markets, with a focus on retinal vascular diseases, cystic fibrosis, geographic atrophy, and alpha-1 antitrypsin deficiency lung disease. The company collaborates with Otsuka Pharmaceutical Co., Ltd., extending its reach in the pharmaceutical industry.

4D Molecular Therapeutics' lead product candidate is 4D-150, intended for retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema. It is designed to deliver sustained anti-VEGF production from the retina via a single intravitreal injection. Another candidate, 4D-710, is in early-stage development for cystic fibrosis. The preclinical pipeline includes 4D-175 for geographic atrophy and 4D-725 for alpha-1 antitrypsin deficiency lung disease. The company also has a collaboration with Otsuka Pharmaceutical Co., Ltd. to advance its programs.